| Literature DB >> 23071398 |
Channy Muhn1, Nathan Rosen, Nowell Solish, Vince Bertucci, Mark Lupin, Alain Dansereau, Fred Weksberg, B Kent Remington, Arthur Swift.
Abstract
Recent advancements, including more versatile facial fillers, refined injection techniques and the adoption of a global facial approach, have contributed to improved patient outcome and increased patient satisfaction. Nine Canadian specialists (eight dermatologists, one plastic surgeon) collaborated to develop an overview on volume restoration and contouring based on published literature and their collective clinical experience. The specialists concurred that optimal results in volume restoration and contouring depend on correcting deficiencies at various layers of the facial envelope. This includes creating a foundation for deep structural support in the supraperiosteal or submuscular plane; volume repletion of subcutaneous fat compartments; and the reestablishment of dermal and subdermal support to minimize cutaneous rhytids, grooves and furrows. It was also agreed that volume restoration and contouring using a global facial approach is essential to create a natural, youthful appearance in facial aesthetics. A comprehensive non-surgical approach should therefore incorporate combining fillers such as high-viscosity, low-molecular-weight hyaluronic acid (LMWHA) for structural support and hyaluronic acid (HA) for lines, grooves and furrows with neuromodulators, lasers and energy devices.Entities:
Keywords: facial rejuvenation; hyaluronic acid filler; volumizing
Year: 2012 PMID: 23071398 PMCID: PMC3469309 DOI: 10.2147/CCID.S30794
Source DB: PubMed Journal: Clin Cosmet Investig Dermatol ISSN: 1178-7015
Five categories of facial filler approved by Health Canada
| Category | Agent | Duration |
|---|---|---|
| High-viscosity, low molecular weight hyaluronic acid (LMWHA) | Voluma (Allergan, Inc) | Long duration (up to 18 months) |
| Hyaluronic acid (HA) | Juvéderm (Allergan, Inc) | Intermediate duration (~12 mo) |
| Restylane (Medicis Aesthetics) | Intermediate duration (~6 mo) | |
| Perlane (Medicis Aesthetics) | ||
| Teosyal (Clarion Medical Technologies) | ||
| Esthelis (Anteis) | ||
| Prevelle (Mentor) | ||
| Revanesse (Prollenium Medical) | ||
| Calcium hydroxylapatite | Radiesse (Merz Aesthetics) | Intermediate duration (~1 yr) |
| Poly-L-lactic acid (PLLA) | Sculptra (Valeant) | Long duration (up to 18 months) |
| Polymethyl methacrylate (PMMA) | Artefill (Artes Medical/suneva) | Permanent (~10 years) |
| Platelet-Rich Fibrin Matrix (PRFM) | Selphyl (Canderm) | Long duration (up to 18 months) |
Note:
Some authors have seen duration of action which is longer than the amounts selphyl (Canderm) listed above.
Figure 1Clinical anatomic cosmetic units considered in soft tissue injections of the face.
Image provided by Allergan, Inc (Irvine, CA).
Figure 2Posterior lateral view showing the cheek ogee curve and pogonion (chin projection).
Image provided by Allergan, Inc (Irvine, CA).
Figure 3Creation of a youthful cheek apex at Swift’s point. (A) Swift’s point is defined as the intersection of a line drawn from the nasal alar groove to the upper tragus and the line drawn vertically down from the midpoint of the lateral orbital rim. (B) Injection for deep hyaluronic acid is overlying bone and periosteum and below muscle where possible.
Note: Subcutaneous injections can be performed with hyaluronic acid over the foundation injection as well.
Images provided by Allergan, Inc (Irvine, CA).
Strategies for volume restoration and contouring in the mid-face with HA
| Treated area | Preferred product | Technique | Dosing | Needles/cannulae (gauge and length) |
|---|---|---|---|---|
| Cheek | HA |
Deep to superficial – lay down a foundation above the periosteum and continue to layer with the goal of restoring natural contours Superior to inferior Medial cheek – subcutaneous Lateral cheek – supraperiosteal and subcutaneous | Mild: 0.5–1 cc/side | Needle: 25–27–29 UTW gauge ½” |
|
| ||||
| TIPS/PEARLS |
Having patient smile and purse lips can help to define unsightly bulges or uneven distribution of product Preferred product has a higher cohesivity with a greater lifting capacity Ensure that the placement of the cheek’s apex is anatomically correct Ovoid, angulated cheek mound Cool ultrasound gel massage for proprioception of smooth blending of product Consider treating medial cheek in subcutaneous plane with a microcannula to minimize risk of angular artery puncture | |||
|
| ||||
| Submalar cheek | HA |
Deep qsubcutaneous | 27–30 gauge needle | |
|
| ||||
| TIPS/PEARLS |
No bony support so deep volume replacement with HA is less effective and will probably require cross-hatching strut work (deep dermal and subdermal) to establish support | |||
|
| ||||
| Tear Trough/Infra-orbital hollows | HA |
Manual anterograde manipulation (gently to avoid bruising) | Use small aliquots (<0.25 cc) | 30–31 gauge ½”–1” or BD tuberculin syringe (backloaded) or 30 g microcannula |
|
| ||||
|
Preferred sub-muscular/supraperiosteal deposition +/− subcutaneous | Rarely need more than 1 cc/side | |||
| TIPS/PEARLS |
It is uncommon for physicians to treat the tear trough in isolation Use a thinner product in this area Tent up the skin where it is thin Injections superior to the infraorbital rim are not recommended unless the injector is highly experienced Use of a 1” needle or microcannula requires fewer puncture sites and results in a smooth, even outcome | |||
|
| ||||
| Nasolabial folds (NLF) | HA |
Superior to inferior Slow bolus injection on pyriform fossa periosteum Anterograde Lower NLF may often benefit from perpendicular struts (bridging) to treat superficial lines and grooves | Mild: <0.5 cc/side | 27–31 gauge 3/8”–½” |
| TIPS/PEARLS |
Use caution and inject vertically without angling upwards when using a needle and going deep due to anatomical structures (eg, angular branch of the facial artery at the apex of the NLF) to minimize risk of intravascular injection or vascular compression leading to ischemia or necrosis Alternatively, the microcannula approach from inferior along the NLF decreases this risk Complete effacement of the NLF is not desirable Cheek should be done prior to NLF; cheek volumizing may have the effect of effacing the lower 2/3 of the NLF Patients with volume loss in cheeks often request NLF filling instead (need for education) Patients with deep NLF and redundant skin respond poorly to NLF filling alone; best to combine with cheek volume augmentation Photos of the patient 20–30 years of age helpful in determining premorbid NLF Always consider filling pyriform fossa to blunt this area and/or narrow the alar base | |||
Note:
General dosing range based on consensus group experience.
Abbreviations: HA, hyaluronic acid; LMWHA, low-molecular-weight hyaluronic acid.
Strategies for volume restoration and contouring in the lower face with HA
| Treated area | Preferred product | Technique | Dosing | Needles/cannulae (gauge and length) |
|---|---|---|---|---|
| Chin | LMWHA/HA |
Layering technique Inject on periosteum for lift and fill Subcutaneous injection to correct irregularities | 27–30 gauge ½” | |
| TIPS/PEARLS |
Chin continues to pre-jowl sulcus and must blend into this area In all cases, consider a neuromodulator to treat the “apple core” chin, mental crease and to increase the longevity of the HA Volume is usually necessary over the entire chin zone extending into the NL as well as the pre-jowl sulcus (PJS) | |||
| Pre-jowl sulcus/marionette | LMWHA/HA |
Deep on bone and subcutaneous | 27–30 gauge ½”–1” | |
| TIPS/PEARLS |
Have the patient sit vertically (90 degrees) so that the lower face is accentuated (fewer re-touches required) Palpability of product may be increased in this area (patient should be informed beforehand); consider manual manipulation to avoid this Only soft tissue around the mouth; no bony prominence to lay the product on Caution not to masculinize the female face | |||
| Post jowl sulcus, mandibular angle and preauricular | LMWHA/HA |
Deep subcutaneous | 27 gauge | |
| TIPS/PEARLS |
Caution not to masculinize the face Do not inject into the parotid gland Mold, blend and feather | |||
Note:
General dosing range based on consensus group experience.
Abbreviations: HA, hyaluronic acid; LMWHA, low-molecular-weight hyaluronic acid.
Figure 4Before and immediately after volume restoration using high-viscosity, low-molecular-weight hyaluronic acid, hyaluronic acid, and onabotulinumtoxinA. Before (A) and after (B) volume restoration using 18 mg/mL gel hyaluronic acid filler, as well as onabotulinumtoxinA for glabellar frown lines and lateral brow. Before (C) and after (D) volume restoration using 24 mg/mL smooth gel hyaluronic acid filler and 24 mg/mL gel filler, as well as onabotulinumtoxinA for eyebrows, glabella, and crow’s feet. Before (E) and after (F) volume restoration using 20 mg/mL smooth, high-viscosity, low-molecular-weight hyaluronic acid for the cheeks, nasolabial folds, and prejowl sulcus. Before (G) and after (H) volume restoration using 24 mg/mL smooth gel hyaluronic acid fillers and 24 mg/mL gel filler.
Photos (A) and (B) courtesy of Dr Nathan Rosen; photos (C) and (D) courtesy of Dr Channy Muhn; photos (E) and (F) courtesy of Dr Fred Weksberg; photos (G) and (H) courtesy of Dr Channy Muhn.
Strategies for volume restoration and contouring in the upper face with HA
| Treated area | Preferred product | Technique | Dosing | Needles/cannulae (gauge and length) |
|---|---|---|---|---|
| Temporal hollow | HA |
Supraperiosteal/intramuscular and subcutaneous | ||
|
Antegrade injection | ||||
|
| ||||
| TIPS/PEARLS |
This is currently an under-recognized zone, but temporal hollow volume restoration can result in dramatic improvements and should be addressed more routinely Most commonly see a plexus of veins that are prominent in this region Tilt the head forward and mark the engorged veins to avoid them with the needle puncture Pushing the needle perpendicularly deep onto the periosteum avoids intravascular deposition even if a vessel is punctured through and through The temporal fusion line will prevent the product’s medial migration Caution due to presence of temporal artery and frontal branch of facial nerve If simultaneously treating masseter hypertrophy, treat masseter with neuromodulator first (results in compensatory hypertrophy of the temporalis muscle) HA results are immediately visible | |||
|
| ||||
| Brow | HA |
Vertical puncture Horizontal/transverse | 0.2–0.5 cc/side | 27 gauge |
|
| ||||
| TIPS/PEARLS |
Forehead, brow and temple are contiguous areas and the relationship between them must be considered when planning treatment of this region Treating the temporal fossa helps with lateral brow positioning and visibility, as the tail of the brow otherwise disappears into the hollow | |||
|
| ||||
| Upper eyelid hollow | HA |
Antegrade deposition on orbital surface of supraorbital rim | Use small aliquots (<0.25 cc) | 30–31 gauge ½”–1” |
|
| ||||
| TIPS/PEARLS |
A youthful upper eyelid has significant volume Aging hollows the supraorbital region Slow injection technique on periosteum with fingers of non-injection hand (“smart hand”) protecting globe and gently molding “less is more” | |||
Note:
General dosing range based on consensus group experience.
Abbreviations: HA, hyaluronic acid; LMWHA, low-molecular-weight hyaluronic acid; Poly-L-lactic acid.